Holiday Notice
PharmaDJ · 09/30/2022
PharmaDJ will take a brief publishing break from October 1 to 9 in observance of China’s National Day holiday.
READ MORE
More MNCs are partnering with Chinese drugmakers in licensing deals
Shi Yingzi · 09/29/2022
August saw eight drug licensing deals, including five in-licensing agreements, an out-licensing deal and two partnerships between domestic companies.
READ MORE
China approved its first homegrown CD20 antibody in August
Danni Yin · 09/19/2022
In August, China saw the approval of only one new molecular entity (NME), Sinocelltech’s CD20 antibody ripertamab (SCT400). Another two homegrown companies, Zelgen and Alphamab, gained new indications and dosing regimens for their self-developed products as well.
READ MORE
Chinese pharma companies raised over half a billon USD in August
Minhua Chu · 09/15/2022
38 biotech companies secured financing this August, 31 of which disclosed figures totaling $563 million.
READ MORE
Four publicly traded drugmakers saw huge investments in July
Minhua Chu · 08/25/2022
Gene therapy, nucleic acid drugs and radiopharmaceuticals are attracting more investor attention.
READ MORE
Kidney disease drugs a hot spot for July in-licensing
Shi Yingzi · 08/18/2022
There were a total of eight drug licensing deals in China in July 2022. This includes four in-licensing agreements, two out-licensing deals and two programs between domestic companies or institutions.
READ MORE
July sees more pan-tumor therapies approved in China
Danni Yin · 08/15/2022
China’s pursuit of innovative oncology drugs remained intense in July, as Chinese regulators granted the first marketing approval for three drugs, namely Simcere’s Cosela (trilaciclib), Lepu Biopharma’s Puyouheng (pucotenlimab) and Roche’s Rozlytrek (Entrectinib).
READ MORE
June in-licensing deals in China biotech drop to a new low
Shi Yingzi · 07/28/2022
In-licensing activity in China’s biotech sector has stayed weak in the second quarter of 2022, with the number of in-licensing deals dropping to a new low in June. Cash-strapped Chinese drugmakers became more prudent in buying and sought big buyers for their assets instead.
READ MORE
Biotech fundraising in China warms up a little in June
Elise Mak · 07/25/2022
After a ‘biotech winter’, it seems the first signs of spring has arrived for the industry. Biotech fundraising trends showed more positive signs in June, with funds raised by Chinese players rising 42% from a month ago to reach $554 million.
READ MORE
READ MORE
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement